Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by MannKind

< Previous 1 2 Next >
INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Corporation Announces Participation at Upcoming Conferences
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Corporation Reports 2023 Third Quarter Financial Results
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 Diabetes
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Corporation to Hold 2023 Third Quarter Financial Results Conference Call on November 7, 2023
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Expands Patent Portfolio With New Clofazimine Formulation Patent
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Corporation Announces Participation at Upcoming Conferences
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Corporation Reports 2023 Second Quarter Financial Results
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Corporation Announces Participation in the 2023 Wedbush PacGrow Healthcare Conference
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Corporation to Hold 2023 Second Quarter Financial Results Conference Call on August 7, 2023
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Launches Inhale-3 Study to Address the Most Important Unmet Need Today in Adults Living With Type 1 Diabetes (T1D)
From MannKind
Via GlobeNewswire
Tickers MNKD
Dr. Burkhard Blank Joins MannKind as Executive Vice President of Research & Development and Chief Medical Officer
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Corporation to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
From MannKind
Via GlobeNewswire
Tickers MNKD
CORRECTION -- MannKind Corporation Reports 2023 First Quarter Financial Results
From MannKind
Via GlobeNewswire
Tickers MNKD
Mannkind Corporation Reports 2023 First Quarter Financial Results
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Corporation to Hold 2023 First Quarter Financial Results Conference Call on May 9, 2023
From MannKind
Via GlobeNewswire
Tickers MNKD
Lauren Sabella Joins Mannkind as Executive Vice President, Chief Operating Officer
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Corporation to Participate in Oppenheimer 33rd Annual Healthcare Conference
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Corporation Reports 2022 Fourth Quarter and Full Year Financial Results
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind to Give Oral Presentation on Meal Challenge Results From the Afrezza® With Basal Combination (ABC Study) at 16th Annual ATTD Conference
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Corporation to Hold 2022 Fourth Quarter and Full Year Financial Results Conference Call on February 23, 2023
From MannKind
Via GlobeNewswire
Tickers MNKD
Mannkind Corporation to Participate in the SVB Securities Global Biopharma Conference
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind Corporation to Participate in the Lytham Partners Investor Select Conference
From MannKind
Via GlobeNewswire
Tickers MNKD
MannKind’s Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung Disease
From MannKind
Via GlobeNewswire
Tickers MNKD
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.